[5,12] More blood vessels means more oxygen, more nutrients, and faster delivery of immune cells to damaged tissue
PMID 41476424
GLP3 + Cagrilintide $174.99 GLP3 + Cagrilintide Blend Peptide combines a triple-action metabolism regulator with an appetite-control peptide, studied for advanced obesity and diabetes research
Total vial exposure time under two minutes

Immune Modulation: The peptide's effects on inflammatory pathways suggest caution for: Active autoimmune conditions Immunocompromised individuals Those taking immunomodulatory medications Populations Requiring Extra Caution Avoid or Use Extreme Caution: Active cancer or history of cancer Pregnancy or breastfeeding Children and adolescents Severe cardiovascular disease Active infections Immediately pre or post-surgery (without medical guidance) Drug Interactions Theoretical Interactions Given BPC-157's mechanisms, theoretical interactions exist with: Medications Affecting NO System: Nitrates (nitroglycerin, isosorbide) PDE5 inhibitors (sildenafil, tadalafil) Some blood pressure medications Reasoning: Combined NO system effects Anticoagulants and Antiplatelets: Warfarin Aspirin Clopidogrel Direct oral anticoagulants Reasoning: Angiogenic effects may affect bleeding Growth Hormone and Related: HGH IGF-1 Other growth-promoting compounds Reasoning: Additive growth factor effects Immunomodulators: Corticosteroids TNF-alpha inhibitors Other immunosuppressants Reasoning: Overlapping immune effects NSAIDs A Special Case Interestingly, while drug interactions are generally concerning, research suggests BPC-157 may protect against NSAID damage

But given the lack of clinical evidence and the fact that BPC-157 peptides are unregulated, we suggest instead that you bring your symptoms, timeline, and goals to a trusted clinician, like one at Midi